TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02779335

Intervention type: OTHER
Group type: OTHER
Intervention: Enteral Formula
Description: pediatric subjects will be fed a standard pediatric enteral formula tube feeding
Study: NCT01063920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-NS001
Description: 1200 mg b.i.d. p.o. for 12 weeks
Study: NCT02677363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
Study: NCT04114240

Intervention type: DRUG
Intervention: Xybilun
Description: Erectil dysfunction, Viagra generic (sildénafil)

Intervention type: DRUG
Intervention: Xybilun
Description: Erectil dysfunction, Viagra generic (sildénafil)

Intervention type: DRUG
Intervention: Xybilun
Description: Erectil dysfunction, Viagra generic (sildénafil)

Intervention type: DRUG
Intervention: Xybilun
Description: Erectil dysfunction, Viagra generic (sildénafil)
Study: NCT03936413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bay Labs EchoGPS Echcoardiogram
Description: An echocardiogram will be performed in this arm using the Bay Labs EchoGPS. The Bay Labs EchoGPS system is an ultrasound system which uses the techniques of computer vision to analyze echocardiography images in real time. It then provides feedback to the user to optimize the images, and once they meet a specific level of quality it automatically records the images.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Native Terason Echocardiogram
Description: An echocardiogram will be performed in this arm using a native Terason echocardiography system. This system will not have any artificial intelligence assistance in image optimization or selection.
Study: NCT05096676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin: Including placebo
Description: Individual received age-dependent dosing of oxytocin and placebo. Participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU.
Study: NCT02161601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricoid Pressure
Description: Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
Study: NCT03903679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway
Description: Patients will be maintained with laryngeal mask airway during the septal surgery.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endotracheal tube
Description: Patients will be maintained with endotracheal tube during the septal surgery.
Study: NCT01512745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT01474447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grinberg Method
Description: The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
Study: NCT04299477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: supra- and subgingival scaling, and root planning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: supra- and subgingival scaling, and root planning
Study: NCT04095572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravesical instillation with HA-CS
Description: intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
Study: NCT01063920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn®
Description: 500 mg b.i.d. p.o. for 12 weeks
Study: NCT04255732

Intervention type: DEVICE
Group type: OTHER
Intervention: extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK
Description: Comparison of the extent of retinal periphery view between two wide field imaging devices.

Intervention type: DEVICE
Group type: OTHER
Intervention: extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany
Description: Comparison of the extent of retinal periphery view between two wide field imaging devices.
Study: NCT01942499

Intervention type: OTHER
Group type: OTHER
Intervention: Community-based exercise program
Study: NCT04095572

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravesical instillation of sterile purified water
Description: intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)
Study: NCT01719237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacine and Chloroprocaine mixture
Description: Chloroprocaine is added to Ropivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine only
Description: Ropivacaine diluted with normal saline instead of chloroprocaine
Study: NCT01536145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
Study: NCT03999905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling training
Description: Online training using Moodle.
Study: NCT03160300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music with Binaural Beats
Description: Relaxing music with embedded binaural beats at a frequency of 5 Hz

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Music
Description: Relaxing music without a binaural beat component
Study: NCT00038441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTI-015
Description: DTI-015 injected through a catheter into center of brain tumor.
Study: NCT01613027

Intervention type: BIOLOGICAL
Intervention: Rituximab
Description: Rituximab administered according to prescribing information and normal clinical practice.
Study: NCT02348853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight for Living (HWL)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Current Best Practice (CBP)
Study: NCT03551808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: using of Ketorolac Tromethamine Eye Drop
Description: using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
Study: NCT02231437

Intervention type: DRUG
Intervention: Berodual®
Study: NCT00672958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated immediate-release tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules.
Study: NCT04422639

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS/SRT
Description: Comparing pre-operative SRS/SRT to post-operative SRS/SRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SRS/SRT
Description: Comparing pre-operative SRS/SRT to post-operative SRS/SRT
Study: NCT01348776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair2Go (Mē)
Description: Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
Study: NCT02240719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study: NCT01108510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: Cobicistat (COBI) 150 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: Ritonavir (RTV) 100 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COBI placebo
Description: Placebo to match COBI administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV placebo
Description: Placebo to match RTV administered orally once daily
Study: NCT03568721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: prescription of ibuprofen 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: prescription of acetaminophen 500 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: prescription of one tablet of chewing gum
Study: NCT02526056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapists
Description: This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elderly people
Description: In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
Study: NCT04924972

Intervention type: PROCEDURE
Intervention: Blepharoplasty
Description: 90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.

Intervention type: PROCEDURE
Intervention: Blepharoplasty
Description: 90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.
Study: NCT05246319

Intervention type: DIAGNOSTIC_TEST
Intervention: preoperative imaging
Description: evaluation of preoperative imaging (versus nodes observed on pathology)
Study: NCT04622137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping therapy
Description: The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
Study: NCT03118544

Intervention type: DEVICE
Intervention: DyeVert System
Description: The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
Study: NCT04521517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
Description: a pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
Study: NCT01440127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
Study: NCT03971812

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
Study: NCT04683523

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Resistance training using dumbbells and therabands

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance training using dumbbells and therabands
Study: NCT00592046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101 (Darinaparsin)
Description: ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
Study: NCT02340702

Intervention type: OTHER
Intervention: COPD
Description: COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of \<0.7.
Study: NCT03289598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals
Description: The intervention consists of two parts:~1. Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~2. The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication.
Study: NCT02664467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips EnergyUp EnergyLight HF3419/01
Description: Bright light therapy (10'000 lux) for 60 minutes after wake-up

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Philips EnergyUp EnergyLight HF3419/01
Description: Placebo dim light (500 lux) for 60 minutes after wake-up
Study: NCT03622398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with HXLPE liner
Description: Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with conventional polyethylene liner
Description: Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
Study: NCT00748189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil, tablets
Description: 2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil, tablets
Description: 2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab (GSK1841157) infusion
Description: iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
Study: NCT02585817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote CIED Management
Description: Information Technology
Study: NCT03096769

Intervention type: OTHER
Group type: OTHER
Intervention: Ergonomist
Description: The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
Study: NCT01849068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg/d for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study: NCT01028638

Intervention type: OTHER
Intervention: 89Zr-bevacizumab PET scan
Description: A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43.
Study: NCT00095745

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Antidepressant + Aripiprazole
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
Study: NCT02222363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX600
Description: Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
Study: NCT04032873

Intervention type: OTHER
Group type: OTHER
Intervention: After Initial Treatment Decision
Description: Monetary cost information is relayed after the initial consult with the treating physician, after the treatment decision is made.
Study: NCT01411995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Description: 3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
Study: NCT00878969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan (ARB)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramipril (ACE inhibitor)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00792246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
Study: NCT00688935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
Study: NCT01411995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water based lubricant
Description: 3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
Study: NCT01420783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT01555320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi Dripping Pills
Description: One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishen Yiqi dripping pills dummy
Description: One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Study: NCT00738673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
Study: NCT01349439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 1mg per Kg (participant weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 1mg per Kg (participant weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 1mg per Kg (participant weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 1mg per Kg (participant weight)

Intervention type: DRUG
Group type: OTHER
Intervention: Short acting + long acting propranolol + memory reactivation
Description: After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
Study: NCT01647984

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ritmonutra
Description: Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02872610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Online
Description: The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager.
Study: NCT04546321

Intervention type: OTHER
Intervention: serum L carnitine level measuring
Description: The serum level of total L carnitine was measured for both HIE and TTN cases

Intervention type: OTHER
Intervention: serum L carnitine level measuring
Description: The serum level of total L carnitine was measured for both HIE and TTN cases